ATNX

Oraxol

Metastatic Breast Cancer

NDA Filing

Exp Date

May-June 2020

Amp Volatility Score

24%

Catalyst Info & Data Links

Catalyst Events

Clinical Trial

  • NCT02594371: Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

Related Links


 

Prior Data & Info Links:

 

Competitive data

 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon